- Poster presentation
- Open Access
Treatment of depersonalization disorder with fluoxetine: a case report
© Saitis et al.; licensee BioMed Central Ltd. 2008
Published: 17 April 2008
One small prospective series and two single case reports had described successful treatment of primary depersonalization disorder in a number of patients treated with fluoxetine [1–3]. But then, one recent randomized, double masked, placebo-controlled trial failed to show efficacy . We present the case of depersonalization disorder that responded favorably to fluoxetine treatment.
Materials and methods
A 23-year old single man had a 1-year history of primary depersonalization disorder. He described feeling “detached from my body, as if I was observing myself from the outside, cut off from emotions and feelings, feeling as if I had completely lost my self and feeling like I was in a dream”. He felt far removed from everything. The patient was treated with fluoxetine 10 mg/day, which was slowly raised to 40 mg/day.
Eight weeks after beginning fluoxetine, the patient had a remarkable improvement. Following complete resolution of the depersonalization symptoms, the patient began to socialize, entertain and work. This is continued for 12 months of follow up.
Fluoxetine may be a promising pharmacological treatment for primary depersonalization disorder.
- Hollander E, Liebowitz MR, DeCaria C, Fairbanks J, Fallon B, Klein DF: Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol. 1990, 10 (3): 200-3. 10.1097/00004714-199006000-00008. JunView ArticlePubMedGoogle Scholar
- Fichtner CG, Horevitz RP, Braun BG: Fluoxetine in depersonalization disorder. Am J Psychiatry. 1992, 149 (12): 1750-1. DecPubMedGoogle Scholar
- Ratliff NB, Kerski D: Depersonalization treated with fluoxetine. Am J Psychiatry. 1995, 152 (11): 1689-90. NovPubMedGoogle Scholar
- Simeon D, Guralnik O, Schmeidler J, Knutelska M: Fluoxetine therapy in depersonalisation disorder: randomised controlled trial. Br J Psychiatry. 2004, 185: 31-6. 10.1192/bjp.185.1.31. JulView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd.